[Current management and future prospect of HER-2 mutant non-small cell lung cancer]

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• HER-2 (Erb-B2 receptor tyrosine kinase 2) is an oncogenic driver in some cancers, notably breast and gastric.
• Unlike in breast cancer, HER-2 targeted therapies show limited efficacy in non-small cell lung cancer (NSCLC).
• HER-2's role in NSCLC is complicated by intragenic kinase domain mutations, distinct from gene copy number variations.

Purpose of the Study:

• To review the pathogenesis and molecular variations of HER-2 mutated NSCLC.
• To summarize clinical features and current therapeutic strategies for HER-2 mutated NSCLC.
• To discuss challenges and future perspectives for treating this patient population.

Main Methods:

• Literature review of studies on HER-2 in NSCLC.
• Analysis of molecular variations, including exon 20 in-frame insertions and kinase domain missense mutations.
• Synthesis of clinical data and treatment outcomes.

Main Results:

• HER-2 intragenic kinase domain mutations, particularly exon 20 insertions, are identified as a distinct mechanism in NSCLC.
• These mutations may explain the poor response to conventional anti-HER-2 and anti-EGFR tyrosine kinase inhibitors (TKIs).
• A growing body of research highlights the need for tailored therapeutic approaches.

Conclusions:

• HER-2 mutations represent a unique subset of NSCLC requiring specific therapeutic strategies.
• Understanding these molecular alterations is crucial for developing effective targeted therapies.
• Further research is needed to overcome treatment challenges and improve outcomes for patients with HER-2 mutated NSCLC.